Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Journey Medical Corp (DERM)

Journey Medical revenue rises 23% to $18.5 million; net loss narrows to $0.3 million

Positive Impact 3 of 5 earnings Written later

Journey Medical reported second-quarter 2026 revenue of $18.5 million, up 23% from $15.0 million a year earlier, with Emrosi contributing $8.1 million. The GAAP net loss narrowed to $0.3 million, or $0.01 per share, from $3.8 million, or $0.16 per share, in the prior-year quarter. The filing gives no financial guidance, and the company reported $25.6 million in cash at June 30, 2026.

Key points

  • Total revenue of $18.5 million for the quarter ended June 30, 2026, up 23% from $15.0 million
  • Emrosi revenue of $8.1 million in the quarter; total prescriptions were approximately 36,000, up from approximately 30,000 in the first quarter of 2026
  • GAAP net loss of $0.3 million, or $(0.01) per share, versus $3.8 million, or $(0.16) per share, a year earlier
  • Cash and cash equivalents of $25.6 million at June 30, 2026; gross margin was 67%, consistent with the prior-year quarter

The filing

CompanyJourney Medical Corp (DERM)
Form8-K, current report
Filed with the SECAug 12, 2026, 4:05 PM ET
Accession number0001104659-26-094862

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:44 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 12, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.